Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KIO-301 · 1 trial · 3 indications
Number of participants with treatment-related adverse events as assessed by overall changes in retinal thickness and appearance, clinical chemistry and hematology, and other eye assessments.
| Arm | Type | Description |
|---|---|---|
| Patients with Retinitis Pigmentosa and Choroideremia | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| KIO-301 | DRUG | KIO-301 intravitreal injection at ascending doses |
Main Study: Inclusion Criteria 1. Be aged 18 to 80 years at Visit 1 of either sex and of any race. 2. Be willing and able to provide informed consent either written, or if the Participant is not able to read, provide consent as stipulated by local laws and Human Research Ethics Committee (HREC) gu...
KIO-301 is an investigational small molecule being developed for the treatment of retinitis pigmentosa, a rare inherited retinal disease. It is administered intravitreally, meaning it is injected into the eye. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
KIO-301 is being developed by Kiora Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KPRX. The company is conducting clinical research on this investigational drug for the treatment of retinitis pigmentosa.
KIO-301 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for safety, tolerability, and efficacy in patients with retinitis pigmentosa.
KIO-301 has one completed clinical trial, identified as NCT05282953, titled the ABACUS study. This was a Phase I/II dose-escalating study evaluating the safety, tolerability, and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia. The trial enrolled 32 participants in Australia.
KIO-301 is a small molecule designed to treat retinitis pigmentosa. It is administered intravitreally, directly into the eye. The specific molecular target of KIO-301 has not been disclosed in available information.